Measles 'out of control,' experts warn, as Alberta case counts surpass 1,000
The province reported another 24 cases on Friday, including 14 in the north zone, nine in the south and one in the Edmonton zone.
This brings the total confirmed cases since the outbreaks began in March to 1,020.
"It is a very grim milestone," said Dr. Karina Top, a pediatric infectious disease physician at the Stollery Children's Hospital in Edmonton, which has been treating children with measles.
"I'm very worried we're going to see more hospitalizations and some deaths soon because we know the death rate is about one to two per thousand. So it's likely that we're going to see that and that will be a very tragic day."
Measles is highly contagious and can lead to serious complications including pneumonia, brain inflammation — which can trigger seizures, deafness and brain damage — as well as premature delivery.
A premature baby who was born with measles died in Ontario recently. And another young child died of measles in that province last year.
Doctors warn there are severe long-term consequences as well, including immune system impacts and a degenerative neurological condition that occurs seven to ten years after an initial measles infection. It is rare but nearly always fatal.
'Out of control'
Alberta's case count has more than doubled in the last month. On May 20, a total of 486 cases had been confirmed.
"This is out of control," said Top.
The hardest hit areas are the south, central and north zones, where there are some very low vaccination rates among young children.
Case counts have been rising quickly in the north zone, which has now topped 200 cases. The south zone has confirmed 681 cases and the central zone has 105.
And health officials are warning the virus is more widespread in those areas than case counts reflect.
"Due to the number of people in these areas who may not be immune to measles, it's likely that some cases are going undetected or unreported," the Alberta government's measles web page states.
"I think we really need to be doing everything we can to engage with those communities that are affected and community leaders to see how best we can work with them to try to get people vaccinated to help contain this infection," said Top.
"And [we need to] get everyone else up to date so that if there are other cases introduced in Edmonton, Calgary or elsewhere in the province, it can be contained more quickly."
University of Calgary infectious disease physician Dr. Dan Gregson is also worried about Alberta's surging measles cases.
"This transmission is just out of the box. It's impossible to contain at the present time," he said.
"The risk, right now, of your child getting measles in Alberta if they're not immunized is pretty high."
Gregson is urging parents who have opted not to immunize their children to rethink that decision.
"If you had made a decision not to vaccinate because measles was not circulating, that's no longer true. We don't have herd immunity. There's measles circulating in the community. And the best way to prevent your child from having a complication would be to get them vaccinated," he said.
The vast majority of Alberta's measles cases are among the unimmunized.
The most recent data shows 85 Albertans have been hospitalized due to this year's outbreaks, including 14 who have ended up in intensive care.
"Most of these hospitalizations are due to patients having pneumonia — they're short of breath, they have to wear oxygen. Some of them are due to brain inflammation. [It's] not a pleasant thing for the parents or the child to have to go through," said Gregson.
In Edmonton, where the Stollery Children's Hospital is treating the sickest patients from northern Alberta, Top said the outbreaks are taking a toll.
"It is distressing as a pediatrician to see children that are sick from a disease that is completely vaccine preventable."
According to provincial data, as of Friday there was one Albertan in ICU due to measles. No deaths have been reported.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Global Telemedicine Market to Grow at 11.3% CAGR Through 2030
"Regional Adoption, Expanding Applications, and Emerging Opportunities Drive Growth in Telemedicine—From Telepsychiatry to IT-Enabled Healthcare Platforms" BOSTON, Aug. 11, 2025 /PRNewswire/ -- According to the latest study from BCC Research, the "Global Markets for Telemedicine Technologies" is projected to grow from $146.9 billion in 2025 to $251.5 billion by the end of 2030, at a compound annual growth rate (CAGR) of 11.3% from 2025 to 2030. This report offers a comprehensive review of the telemedicine technologies market, focusing on its rapid growth. key players and their competitive strategies, innovations, and regional opportunities, while also examining market drivers like virtual consultations and patient demand for remote care. The market is segmented by hardware, software, and services, and categorized by end-users such as homes and healthcare providers. It also explores emerging technologies, regulatory landscapes, and trends across major regions and countries. Overall, the report underscores telemedicine's expanding role in modern healthcare, driven by digital tools, remote monitoring, and increasing patient adoption. This report is particularly relevant today because telemedicine has gained widespread acceptance following the COVID-19 pandemic, particularly in urban areas. It offers a vital solution for people in rural or remote regions to access healthcare services. Beyond consultations, telemedicine enables patients to undergo regular check-ups, diagnoses, imaging, and even surgeries through virtual platforms. With reduced waiting times and increased convenience, telemedicine has become one of the most efficient ways to connect with physicians and receive timely care. The factors driving the market's growth include: Growing Trend of Asynchronous Telemedicine: Asynchronous telemedicine allows patients and healthcare providers to communicate without needing to be online at the same time. This includes sharing medical data, images, or messages through secure platforms. It enhances flexibility, reduces wait times, and expands access to care, especially in rural or underserved areas. Implementation of the Internet of Things in Telemedicine: IoT devices like wearables and remote sensors are transforming telemedicine by enabling real-time health monitoring. These tools collect and transmit patient data continuously, allowing for timely interventions and personalized care. This integration boosts efficiency and supports proactive healthcare delivery. Telemedicine for Chronic Disease Management: Telemedicine is increasingly used to manage chronic conditions such as diabetes, hypertension, and heart disease. It facilitates regular virtual consultations, remote monitoring, and patient education, helping reduce hospital visits and improve long-term health outcomes through consistent care. Advances in Digital Healthcare Systems: Modern digital healthcare systems, including electronic health records (EHRs) and AI-powered diagnostics, are streamlining telemedicine services. These technologies improve data sharing, enhance decision-making, and support integrated care models, making telemedicine more effective and scalable. Evolving Insurance Sectors for Telemedicine: Insurance providers are adapting to the rise of telemedicine by expanding coverage for virtual consultations and remote care services. This shift makes telemedicine more accessible and affordable, encouraging broader adoption among patients and healthcare providers alike. Request a sample copy of the global market for telemedicine technologies report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $133.7 billion Market size forecast $251.5 billion Growth rate CAGR of 11.3% from 2025 to 2030 Segments covered Application, Business Area, End User, and Region Regions covered North America, Europe, Asia-Pacific, South America and the Middle East and Africa (MEA) Countries covered U.S., Canada, Germany, the U.K., Italy, France, Spain, Japan, China, India, South Korea, Australia, Brazil, Mexico and Argentina Market drivers • Growing trend of asynchronous telemedicine. • Implementation of the Internet of Things in telemedicine. • Use of telemedicine for chronic disease management. • Advances in digital healthcare systems. • Evolving insurance sectors for telemedicine. Interesting facts: Telemedicine technology will likely reduce the number of in-patient visits in hospitals, clinics and other healthcare systems. Telesurgery has been successful in countries like South Korea, India, and China in performing surgery using robotics, smart devices, and video calling from anywhere. Emerging startups: Sprinter Health: Sprinter Health focuses on reaching patients who cannot contact any healthcare system. The company provides a clinician network and a tech platform to solve problems by bringing critical preventive care to disabled patients. Orange Health: Orange Health is among the fastest-growing diagnostic-tech companies in India. The company provides consumers with 60 mintues of at-home testing for over 2,000 tests with fast results. Bug Sense Diagnostics: Bug Sense has developed a low-cost, fast, easy-to-use point-of-care diagnostic device for urinary tract infections (UTIs). BugSense provides the same accuracy as other culture devices but does not require an incubation machine or other medical devices. The report addresses the following questions: What are the projected size and growth rate for the global market for telemedicine technologies? The global market for telemedicine technologies was valued at $133.7 billion in 2024. The telecardiology segment recorded a value of $28.3 billion in 2024, which is projected to grow at a CAGR of 14.1% during the forecast period. 2. Which market segments are covered in the report? The global market for telemedicine technologies is segmented by: Business Area. End-user. Application. 3. Which business area will be dominant through 2030? Services are expected to be the dominant business area through the end of the forecast period. 4. Which application market is growing fastest? Telecardiology and telepsychiatry applications are the fastest-growing markets. Market leaders include: AMERICAN WELL AMC HEALTH CISCO SYSTEMS INC. CVS HEALTH DOXIMITY INC. GE HEALTHCARE GLOBALMED HOLDINGS LLC. IMEDTAC CO. LTD. KONINKLIJKE PHILIPS N.V. MEDTRONIC SIEMENS HEALTHINIEERS AG SHL TELEMEDICINE TELADOC HEALTH INC. TELESPECIALISTS TIGERCONNECT Related reports: Elder Care Services and Assistive Devices: Global Markets: This report highlights key trends shaping the elder care services and assistive devices market. It explores how factors like R&D, technological innovations, and government initiatives are driving growth, while also addressing challenges such as rising competition. The study provides insights into strategic moves like M&A and collaborations, evaluating their strengths and weaknesses in the context of evolving customer needs and emerging technologies. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo: View original content to download multimedia: SOURCE BCC Research LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
Trump says his administration looking at reclassifying marijuana
President Donald Trump on Monday confirmed he and his administration are considering reclassifying marijuana as a less dangerous drug. Trump told reporters that it was early in the process but that he hoped to make a decision on the matter within the coming weeks. "We're looking at reclassification and we'll make a determination over the next -- I would say over the next few weeks, and that determination hopefully will be the right one. It's very complicated subject," Trump said as he held a news conference in the White House briefing room. Trump was in the briefing room to announce a federal takeover of Washington's police force and deployment of the National Guard to deal, he said, with the city's crime and homelessness. He was asked at the news conference if reclassifying marijuana would send mixed messages as his administration says it wants to "clean up" crime in the nation's capital and potentially other cities. The Wall Street Journal first reported that Trump was weighing rescheduling marijuana from a Schedule 1 drug to a Schedule 3 drug. Classified as a Schedule 1 drug, marijuana is listed alongside heroin and LSD as "drugs with no currently accepted medical use and a high potential for abuse." By contrast, Schedule 3 drugs are define as those with "moderate to low potential for physical and psychological dependence" and include ketamine, anabolic steroids and testosterone. During the final year of the Biden administration, the Drug Enforcement Administration said it supported recommending the reclassification of marijuana. Reclassifying marijuana would allow for more research into the drug and provide tax benefits to the cannabis industry. Trump on Monday said he's heard good and bad things regarding the drug. "I've heard great things having to do with medical, and I've had bad things having to do with just about everything else. But medical, and, you know, for pain and various things," Trump said. "Some people like it, some people hate it," the president said.
Medscape
34 minutes ago
- Medscape
Lessons for Parkinson's From MS, and Vice Versa
This transcript has been edited for clarity. Indu Subramanian, MD: Hi, everyone. Welcome to Medscape. I'm so excited to have my friend and colleague, Prof Lorraine Kalia, join us today to talk about a very cool topic: what we can learn from multiple sclerosis (MS) studies and therapies, and how we can maybe translate that to some of the problems that we've been having in the Parkinson's world. Prof Lorraine Kalia is a clinical scientist at the Krembil Institute. She's also an amazing neurologist at the University of Toronto, which is my alma mater. Welcome, Lorraine. Lorraine V. Kalia, MD, PhD: Hi, Indu. Thanks for having me. Meeting of MS and PD Minds Subramanian: My name is Dr Indu Subramanian. I'm based at UCLA. Maybe we can get right into this. You had this very cool meeting in November 2022, and you had experts in the MS world as well as the Parkinson's disease world. Tell us a little bit about what inspired that meeting in the first place. Kalia: It's a bit of a personal story, actually. I might date myself a little bit, but I was a medical student during the time of the natalizumab development. At that time, I thought I was going to be an MS neurologist. Even back then, they already had a couple of disease-modifying therapies for MS and I thought, You know what, I think MS is good. I think they're in good shape. As a scientist with an understanding of the biology behind disease, it was clear to me that there still was a large amount of work needing to be done in Parkinson's disease because that's obviously how we translate things into having disease-modifying therapies. That was part of the reason — not the only reason — why I shifted into the movement disorder space. Fast-forward many years later: I often give talks around the lack of disease-modifying therapies for Parkinson's disease by introducing MS. Sometimes when you ask why we don't have a disease-modifying therapy for Parkinson's, people throw up their hands and say, "Well, you know, neurologic diseases are complicated." I'll often use the MS example to demonstrate that actually there is much that can be done in the neurologic space and there's been a lot of successes in MS. I was once giving this talk, and as a consequence of this talk, had a conversation with Parkinson Canada who thought, wow, that's an interesting idea around MS being so successful and PD lagging behind. We came up with the idea of having a meeting in Toronto. We obviously have very strong Parkinson's researchers in Toronto, but also a very strong MS team at the Saint Michael's Hospital. I collaborated with a colleague — actually, we were residents together — to bring world experts to Toronto to sit around a table, which is what we did, and talk about where we are in MS and where we are in Parkinson's disease. We were looking for common ground but also looking to see what is different and how we might think about things differently that might have led to the different paths that we've experienced in our fields. Lessons From MS Subramanian: What do you think some take-home messages for the clinician would be from that discussion? I think it was a very cool paper. Kalia: Maybe the take-home messages is it's complicated, which is not as simple as I had hoped. I hoped that we'd come back with clear messages of what we really need to do with Parkinson's. I think we found common ground for one thing. I think it's fair to say that MS has done remarkably well at treating inflammation. All of their drugs are based on that, and they will recognize that they have challenges in terms of treating the neurodegenerative part of their condition. Now that we increasingly recognize that inflammation is a part of Parkinson's disease and there's increased work around the immune basis to the disease, I think we are going to be able to take advantage of what MS has done and learn to hopefully make advances that way. For anybody who's learned about MS , its successes have hanged heavily on its neuroimaging biomarkers of MRI. Of course, biomarkers are needed for the development of Parkinson's disease , and perhaps more work into the neuroimaging piece as well as the biospecimen biomarkers is key to starting to be able to have different kinds of outcome measures. Not the clinical outcome measures that we're using right now in basically all of our clinical trials, but to have early biomarker outcome measures that will help to inform us for our later clinical trials. The other commonality between the two is this concept of earlier disease. We have our prodromal Parkinson's disease and MS has their radiologically isolated syndrome. Up until now, logically, it has made sense to us that we should treat earlier in Parkinson's disease, and that will likely give us better successes. In the MS space, there's actually proof of that. They have clinical trials showing the benefit of treating people in the radiologically isolated syndrome state. While in Parkinson's disease, it has been theoretical and seems to make sense to all of us, we don't have any hard proof to say that treating earlier is better, whereas in MS they have already demonstrated that. I think this then provides us with actual proof in the pudding that that approach really does have implications for disease progression. PD Ahead of MS for Lifestyle Subramanian: Absolutely. I think both diseases in many ways have revolutionized since back in the day when we were in training. The MS models have really come a long way, with many patients doing very well for a long time. I think we have to really take a look at where our feelings are and how we can do better. I'm excited just about the concept of identifying people early and then getting people who may be even at risk for developing Parkinson's into lifestyle measures and wellness choices. I think MS has done a great job of that as well. Can you speak a little bit about that from your own perspective? Kalia: I don't think it came out in the paper, but it came out in our discussions that as a field and as a patient population, there's probably been more embrace of lifestyle measures and physical activity in Parkinson's, which I think is kudos to us in Parkinson's disease. Maybe it's in part because in MS they have these drugs that came through one after another after another, and there's this heavy pharma management of MS that they haven't had to explore the lifestyle assets. There's a large amount that MS has to learn from Parkinson's disease, in terms of putting in place so many of the things that we discuss in Parkinson's, whether it be diet, sleep, stress or mindfulness — all of these things. I think that in Parkinson's, we're further ahead. Subramanian: Absolutely. I agree with you. I'm excited to learn from these other disease states that we train under in residency. We see these patients and we can open our minds to looking at different lenses, for sure. Thank you so much for spending the time and chatting about this. Kudos to you for having that meeting. It sounds like a great opportunity to bring great minds together. Kalia: Yes. Hopefully, we can do more of this in the future. Subramanian: Go Canada. Thank you for joining us, everyone.
